Mark J. Karbarz

1.9k total citations · 1 hit paper
24 papers, 1.5k citations indexed

About

Mark J. Karbarz is a scholar working on Pharmacology, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Mark J. Karbarz has authored 24 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pharmacology, 7 papers in Cardiology and Cardiovascular Medicine and 6 papers in Molecular Biology. Recurrent topics in Mark J. Karbarz's work include Cannabis and Cannabinoid Research (9 papers), Atrial Fibrillation Management and Outcomes (7 papers) and Alcohol Consumption and Health Effects (5 papers). Mark J. Karbarz is often cited by papers focused on Cannabis and Cannabinoid Research (9 papers), Atrial Fibrillation Management and Outcomes (7 papers) and Alcohol Consumption and Health Effects (5 papers). Mark J. Karbarz collaborates with scholars based in United States, Canada and France. Mark J. Karbarz's co-authors include Christian R.H. Raetz, Genmin Lu, Pamela B. Conley, Athiwat Hutchaleelaha, Robert J. Cotter, Uma Sinha, Stanley J. Hollenbach, Francis DeGuzman, Keith Abe and Peng Luan and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Blood.

In The Last Decade

Mark J. Karbarz

24 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

2013 533 citations Genmin Lu, Francis DeGuzman et al. Nature Medicine profile →

Peers

Countries citing papers authored by Mark J. Karbarz

Since Specialization

Citations

This map shows the geographic impact of Mark J. Karbarz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Karbarz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Karbarz more than expected).

Fields of papers citing papers by Mark J. Karbarz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Karbarz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Karbarz. The network helps show where Mark J. Karbarz may publish in the future.

Co-authorship network of co-authors of Mark J. Karbarz

This figure shows the co-authorship network connecting the top 25 collaborators of Mark J. Karbarz. A scholar is included among the top collaborators of Mark J. Karbarz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark J. Karbarz. Mark J. Karbarz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Heteroarylureas with fused bicyclic diamine cores as inhibitors of fatty acid amide hydrolase 2020 ·Bioorganic & Medicinal Chemistry Letters ·John M. Keith, W. M. Jones, (unknown), Mark Seierstad, James A. Palmer, Michael Webb, Mark J. Karbarz, Brian Scott, Sandy J. Wilson, Lin Luo, Michelle Wennerholm, Leon Chang, Michèle Rizzolio, (unknown), Sandra R. Chaplan, J. Guy Breitenbucher	4
2	A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers 2020 ·Blood Advances ·Genmin Lu, Pamela B. Conley, Janet M. Leeds, Mark J. Karbarz, Gallia G. Levy, Vandana Mathur, Janice Castillo, Mark Crowther, John T. Curnutte	28
3	Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa 2017 ·Blood Advances ·Deborah Siegal, Genmin Lu, Janet M. Leeds, Mark J. Karbarz, Janice Castillo, Vandana Mathur, Athiwat Hutchaleelaha, Uma Sinha, Michael M. Kitt, (unknown), Stanley J. Hollenbach, John T. Curnutte, Pamela B. Conley, Mark Crowther	52
4	The SAR of brain penetration for a series of heteroaryl urea FAAH inhibitors 2016 ·Bioorganic & Medicinal Chemistry Letters ·John M. Keith, Mark S. Tichenor, Richard L. Apodaca, Wei Xiao, W. M. Jones, Mark Seierstad, (unknown), James A. Palmer, Michael Webb, Mark J. Karbarz, Brian Scott, Sandy J. Wilson, Michelle Wennerholm, Michèle Rizzolio, (unknown), Sandra R. Chaplan, J. Guy Breitenbucher	11
5	Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolase 2014 ·Bioorganic & Medicinal Chemistry Letters ·John M. Keith, W. M. Jones, (unknown), Mark Seierstad, James A. Palmer, Michael Webb, Mark J. Karbarz, Brian Scott, Sandy J. Wilson, Lin Luo, Michelle Wennerholm, Leon Chang, Sean M. Brown, Michèle Rizzolio, (unknown), Sandra R. Chaplan, J. Guy Breitenbucher	24
6	1-Aryl-2-((6-aryl)pyrimidin-4-yl)amino)ethanols as competitive inhibitors of fatty acid amide hydrolase 2014 ·Bioorganic & Medicinal Chemistry Letters ·John M. Keith, Natalie A. Hawryluk, Richard L. Apodaca, (unknown), (unknown), Mark Seierstad, James A. Palmer, Michael Webb, Mark J. Karbarz, Brian Scott, Sandy J. Wilson, Lin Luo, Michelle Wennerholm, Leon Chang, Michèle Rizzolio, Sandra R. Chaplan, J. Guy Breitenbucher	11
7	A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa breakdown → 2013 ·Nature Medicine ·Genmin Lu, Francis DeGuzman, Stanley J. Hollenbach, Mark J. Karbarz, Keith Abe, (unknown), Peng Luan, Athiwat Hutchaleelaha, Mayuko Inagaki, Pamela B. Conley, David R. Phillips, Uma Sinha	533
8	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors 2013 ·Blood ·(unknown), (unknown), (unknown), Genmin Lu, Pamela B. Conley, (unknown), Janice Castillo, Athiwat Hutchaleelaha, Mark J. Karbarz, (unknown), (unknown), (unknown), Gallia G. Levy, Stuart J. Connolly, John T. Curnutte	99
9	Abstract 10: Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Pharmacokinetic and Pharmacodynamic Study of PRT064445, a Universal Antidote for Factor Xa Inhibitors 2013 ·Arteriosclerosis Thrombosis and Vascular Biology ·Mark Crowther, (unknown), Matthew W. McClure, Uma Sinha, Genmin Lu, Mark J. Karbarz, Athiwat Hutchaleelaha, (unknown), Vandana Mathur, John T. Curnutte	34
10	Heteroaryl urea inhibitors of fatty acid amide hydrolase: Structure–mutagenicity relationships for arylamine metabolites 2012 ·Bioorganic & Medicinal Chemistry Letters ·Mark S. Tichenor, John M. Keith, W. M. Jones, (unknown), (unknown), Natalie A. Hawryluk, Mark Seierstad, James A. Palmer, Michael Webb, Mark J. Karbarz, Sandy J. Wilson, Michelle Wennerholm, (unknown), D. Beerens, Lin Luo, Sean M. Brown, Marlies De Boeck, Sandra R. Chaplan, J. Guy Breitenbucher	20
11	Biochemical and Biological Properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a Mechanism-Based Inhibitor of Fatty Acid Amide Hydrolase 2008 ·Anesthesia & Analgesia ·Mark J. Karbarz, Lin Luo, Leon Chang, Chui‐Se Tham, James A. Palmer, Sandy J. Wilson, Michelle Wennerholm, Sean M. Brown, Brian Scott, Richard L. Apodaca, John M. Keith, Jiejun Wu, J. Guy Breitenbucher, Sandra R. Chaplan, Michael Webb	61
12	Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase 2008 ·Bioorganic & Medicinal Chemistry Letters ·John M. Keith, Richard L. Apodaca, Wei Xiao, Mark Seierstad, Kanaka Pattabiraman, Jiejun Wu, Michael Webb, Mark J. Karbarz, Sean M. Brown, Sandy Wilson, Brian Scott, Chui‐Se Tham, Lin Luo, James A. Palmer, Michelle Wennerholm, Sandra R. Chaplan, J. Guy Breitenbucher	76
13	Purification and Characterization of the Lipid A 1-Phosphatase LpxE of Rhizobium leguminosarum 2008 ·Journal of Biological Chemistry ·Mark J. Karbarz, David A. Six, Christian R.H. Raetz	22
14	Interaction of Group IA Phospholipase A₂ with Metal Ions and Phospholipid Vesicles Probed with Deuterium Exchange Mass Spectrometry 2008 ·Biochemistry ·John E. Burke, Mark J. Karbarz, Raymond A. Deems, Sheng Li, Virgil L. Woods, Edward A. Dennis	49
15	Periplasmic Cleavage and Modification of the 1-Phosphate Group of Helicobacter pylori Lipid A 2004 ·Journal of Biological Chemistry ·An X. Tran, Mark J. Karbarz, Xiaoyuan Wang, Christian R.H. Raetz, Sara C. McGrath, Robert J. Cotter, M. Stephen Trent	78
16	MsbA Transporter-dependent Lipid A 1-Dephosphorylation on the Periplasmic Surface of the Inner Membrane 2004 ·Journal of Biological Chemistry ·Xiaoyuan Wang, Mark J. Karbarz, Sara C. McGrath, Robert J. Cotter, Christian R.H. Raetz	99
17	Enzymatic Synthesis of Lipid A Molecules with Four Amide-linked Acyl Chains 2004 ·Journal of Biological Chemistry ·C. Sweet, Allison H. Williams, Mark J. Karbarz, Catherine Werts, Suzanne R. Kalb, Robert J. Cotter, Christian R.H. Raetz	31
18	Origin of the 2-Amino-2-deoxy-gluconate Unit inRhizobium leguminosarum Lipid A 2003 ·Journal of Biological Chemistry ·(unknown), Mark J. Karbarz, Suzanne R. Kalb, Robert J. Cotter, Christian R.H. Raetz	31
19	Expression Cloning and Biochemical Characterization of a Rhizobium leguminosarum Lipid A 1-Phosphatase 2003 ·Journal of Biological Chemistry ·Mark J. Karbarz, Suzanne R. Kalb, Robert J. Cotter, Christian R.H. Raetz	54
20	Expression Cloning and Characterization of the C28 Acyltransferase of Lipid A Biosynthesis in Rhizobium leguminosarum 2002 ·Journal of Biological Chemistry ·Shib Sankar Basu, Mark J. Karbarz, Christian R.H. Raetz	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact